Hart RG, Halperin JL. Atrial fibrillation and stroke: concepts and controversies. Stroke. 2001;32(3):803–8.
January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071–104.
Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123(7):638-645.e634.
Lang K, Bozkaya D, Patel AA, et al. Anticoagulant use for the prevention of stroke in patients with atrial fibrillation: findings from a multi-payer analysis. BMC Health Serv Res. 2014;14:329.
Kakkar AK, Mueller I, Bassand J-P, et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J. 2012;163(1):13-19.e11.
Patel AA, Lennert B, Macomson B, et al. Anticoagulant use for prevention of stroke in a commercial population with atrial fibrillation. Am Health Drug Benefits. 2012;5(5):291–8.
Reynolds MR, Shah J, Essebag V, et al. Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry. Am J Cardiol. 2006;97(4):538–43.
Ogilvie IM, Welner SA, Cowell W, Lip GY. Characterization of the proportion of untreated and antiplatelet therapy treated patients with atrial fibrillation. Am J Cardiol. 2011;108(1):151–61.
Alamneh EA, Chalmers L, Bereznicki LR. Suboptimal use of oral anticoagulants in atrial fibrillation: has the introduction of direct oral anticoagulants improved prescribing practices? Am J Cardiovasc Drugs. 2016;16(3):183–200.
Hernandez I, Zhang Y, Saba S. Comparison of the effectiveness and safety of apixaban, dabigatran, rivaroxaban and warfarin in newly diagnosed atrial fibrillation. Am J Cardiol. 2017;120(10):1813–9.
Hernandez I, Saba S, Zhang Y. Geographic variation in the use of oral anticoagulation in stroke prevention in atrial fibrillation. Stroke. 48:2289–2291.
Marzec LN, Wang J, Shah ND, et al. Influence of direct oral anticoagulants on rates of oral anticoagulation for atrial fibrillation. J Am Coll Cardiol. 2017;69(20):2475–84.
Hsu JC, Maddox TM, Kennedy KF, et al. Oral anticoagulant therapy prescription in patients with atrial fibrillation across the spectrum of stroke risk: insights from the NCDR PINNACLE Registry. JAMA Cardiol. 2016;1(1):55–62.
Yao X, Abraham NS, Alexander GC, et al. Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. J Am Heart Assoc 2016;5(2).
Borne RT, O’Donnell C, Turakhia MP, et al. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the Veterans Health Administration. BMC Cardiovasc Disorders. 2017;17(1):236. https://doi.org/10.1186/s12872-017-0671-6.
Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009;104(11):1534–9.
Crivera C, Nelson WW, Bookhart B, et al. Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medications. Curr Med Res Opin. 2015;31(10):1889–95. https://doi.org/10.1185/03007995.2015.1077213.
Center for Medicare and Medicaid Services Chronic Conditions Data Warehouse. 27 Chronic Condition Algorithm. https://www.ccwdata.org/cs/groups/public/documents/document/ccw_condition_categories.pdf Accessed April 26, 2017.
Kumamaru H, Judd SE, Curtis JR, et al. Validity of claims-based stroke algorithms in contemporary Medicare data: reasons for geographic and racial differences in stroke (REGARDS) study linked with Medicare claims. Circ Cardiovasc Qual Outcomes. 2014;7(4):611–9.
Lo-Ciganic WH, Donohue JM, Jones BL, et al. Trajectories of diabetes medication adherence and hospitalization risk: a retrospective cohort study in a large state Medicaid program. J Gen Intern Med. 2016;31(9):1052–60. https://doi.org/10.1007/s11606-016-3747-6.
Lo-Ciganic WH, Donohue JM, Thorpe JM, et al. Using machine learning to examine medication adherence thresholds and risk of hospitalization. Med Care. 2015;53(8):720–8.
Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016;5(6):e003725. https://doi.org/10.1161/jaha.116.003725.
Zalesak M, Siu K, Francis K, et al. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes. 2013;6(5):567–74.
Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–72.
Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–100.
Coleman CI, Peacock WF, Bunz TJ, Alberts MJ. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and previous stroke or transient ischemic attack. Stroke. 2017;48(8):2142–9.
Desai NR, Krumme AA, Schneeweiss S, et al. Patterns of initiation of oral anticoagulants in patients with atrial fibrillation—quality and cost implications. Am J Med. 2014;127(11):1075-1082.e1071.
Hernandez I, Zhang Y, Brooks MM, Chin PK, Saba S. Anticoagulation use and clinical outcomes after major bleeding on dabigatran or warfarin in atrial fibrillation. Stroke. 2017;48(1):159–66.
Abraham NS, Singh S, Alexander GC, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ. 2015;350:h1857.
Hernandez I, Baik SH, Pinera A, Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med. 2015;175(1):18–24.
Hernandez I, Zhang Y. Comparing stroke and bleeding with rivaroxaban and dabigatran in atrial fibrillation: analysis of the US Medicare Part D data. Am J Cardiovasc Drug. 2017;17(1):37–47.
Gray M, Saba S, Zhang Y, Hernandez I. Outcomes of atrial fibrillation patients newly recommended for oral anticoagulation under the 2014 AHA/ACC/HRS guideline. J Am Heart Assn 7(1):e007881.
Hernandez I, Zhang Y, Saba S. Effectiveness and safety of direct oral anticoagulants and warfarin, stratified by stroke risk in patients with atrial fibrillation. Am J Cardiol. 2018;122(1):69–75.
Peterson ED, Pokorney SD. New treatment options fail to close the anticoagulation gap in atrial fibrillation. J Am Coll Cardiol. 2017;69(20):2485–7.
Hess PL, Mirro MJ, Diener HC, et al. Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012. Am Heart J. 2014;168(3):239-247.e231.
Caro JJ. An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation. Am J Manag Care. 2004;10(14 Suppl):S451–8.
Patel AA, Ogden K, Veerman M, Mody SH, Nelson WW, Neil N. The economic burden to Medicare of stroke events in atrial fibrillation populations with and without thromboprophylaxis. Popul Health Manag. 2014;17(3):159–65.
Shrank WH, Patrick AR, Brookhart MA. Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. J Gen Intern Med. 2011;26(5):546–50.
Andersohn F, Willich SN. The healthy adherer effect. Arch Intern Med. 2009;169(17):1633–8.